HLB BioStep Co

HLB BioStep Co P/CF

The P/CF (Price-to-Cash-Flow Ratio) of HLB BioStep Co (278650.KQ) as of Oct 22, 2026 is 34.57. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -9.14 — a change of -478.15% (higher).

P/CF

34.57

YoY

-478.15%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of HLB BioStep Co is 2025 34.57 . P/CF (Price-to-Cash-Flow Ratio) of HLB BioStep Co was 2024 -9.14 . It decreases by -478.15% higher compared to the previous year.

The HLB BioStep Co P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2018
20.59 KRW
Jan 1, 2019
20.59 KRW
Jan 1, 2020
9.31 KRW
Jan 1, 2021
12.61 KRW
Jan 1, 2022
16.46 KRW
Jan 1, 2023
20.55 KRW
Jan 1, 2024
-9.14 KRW
Jan 1, 2025
34.57 KRW
The HLB BioStep Co P/CF history
YEARP/CFYoY
34.57-478.15%
-9.14-144.49%
20.55+24.83%
16.46+30.59%
12.61+35.46%
9.31-54.80%
20.590.00%
20.590.00%
20.59-39.52%
34.04—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

HLB BioStep Co Stock analysis

What does HLB BioStep Co do? HLB bioStep Co., Ltd. generates revenue through three business segments. The Non-clinical Test Consignment Agency Business segment provides testing for new drugs and evaluates efficacy, pharmacodynamics, and safety of substances. The Bioinfra Business segment designs, constructs, and maintains animal laboratories while delivering equipment. The Pet Medical Business segment develops veterinary medicine and sells companion animal products. Clients include pharmaceutical companies requiring non-clinical testing, research institutions needing laboratory infrastructure, and pet care providers purchasing animal health products. The company's Non-clinical Test Consignment Agency Business serves pharmaceutical firms seeking pre-market substance evaluation. Bioinfra Business targets institutions requiring specialized animal lab facilities and equipment. Pet Medical Business supplies veterinary medicine to pet health markets. Revenue streams are derived from testing fees, laboratory services, equipment sales, and product distribution. HLB bioStep's segments align with pharmaceutical development cycles, animal research infrastructure needs, and companion animal healthcare demands. Testing services are contracted by drug developers, lab construction by research organizations, and veterinary products sold to pet care retailers. The company monetizes expertise in non-clinical testing, lab management, and veterinary product distribution without direct consumer sales. HLB BioStep Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HLB BioStep Co stock

P/CF (Price-to-Cash-Flow Ratio) of HLB BioStep Co is 34.57 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of HLB BioStep Co changed from -9.14 to 34.57, representing a -478.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) HLB BioStep Co since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s HLB BioStep Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — HLB BioStep Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — HLB BioStep Co